Hodgkin’s lymphoma: 2023 update on treatment

Sicong Zhang; Xianming Liu; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Xianhuo Wang; Huilai Zhang

doi:10.20892/j.issn.2095-3941.2023.0427

Article Figures & Data

Tables

View popup

Table 1

Progress in developing novel therapies for HL in 2023

HL	Study population	Sample size	Regimen	Results	Refs
Early-stage HL	Early-stage HL with ≥ 1 unfavorable EORTC/LYSA criterion	170	BV-AVD followed by 30 Gy of radiotherapy	PET-negative rate 82.3%; 2 y PFS 90.9%	²
Advanced HL	≥ 12 y with stage 3–4 HL	994	N-AVD	1 y PFS 94%	³
	Pediatric and adolescent HL with SER (Deauville score 4 or 5)	49	Two cycles of OEPA + pembrolizumab + COPDAC-28	86% had LRA; 64% PET negative by BICR	⁴
	Advanced-stage cHL	1500	PET2-guided BrECADD	3 y PFS 94.9%	⁵
	Pediatric and adolescent HL	600	BV-AVEPC	Complete metabolic response 89.7%; 3 y EFS 92.1%	⁶
Relapsed/refractory disease	R/R cHL	59	BV + nivolumab	18-month PFS 94%	⁷
	R/R cHL	260	Anti-PD-1	3 y PFS 55.1%; 3 y OS 89.7%	⁸
	CAYA (5–30 years of age) with R/R cHL	44	Nivolumab + BV followed by BV + bendamustine in patients with suboptimal response	CMR 94% any time before consolidation; 1 y PFS 91%	⁹
	Anti-PD-1 or PD-L1 treatment-resistant cHL	24	IBI322 (anti-CD47/PD-L1 bispecific antibody)	ORR 47.8%; disease control rate 91.3%	¹⁰
	R/R HL	16	CD30.CAR EBVST	ORR 75%	¹¹
Older patients	ABVD-unfit, older patients with advanced cHL	27	Pembrolizumab	Response rate 72%; 12-month OS 90%; 24-month OS 83%	¹²
Older patients	Older adults with cHL	37	N-AVD	ORR 100%; CR 97%; 2 y PFS 86.2%; 2 y OS 96.4%	¹³

HL, Hodgkin’s lymphoma; BV, brentuximab vedotin; AVD, doxorubicin, vinblastine, and dacarbazine; N, nivolumab; PET, positron emission tomography; EORTC, European Organisation for Research and Treatment of Cancer; LYSA, Lymphoma Study Association; y, year; PFS, progression-free survival; ORR, objective response rate; CR, complete remission; EFS, event-free survival; AVEPC, doxorubicin, vincristine, etoposide, prednisone, cyclophosphamide; OPEA, vincristine, etoposide, prednisone/prednisolone, and doxorubicin; COPDAC-28, 4 cycles of cyclophosphamide, vincristine, prednisone/prednisolone, dacarbazine LRA, late response assessment; BICR, blinded independent central review; cHL, classic Hodgkin lymphoma; CD30.CAR EBVST, CD30.CAR-modified Epstein-Barr virus-specific T cells; CAYA, children, adolescents, and young adults.